Natixis Advisors LLC boosted its stake in shares of Cabot Corporation (NYSE:CBT - Free Report) by 14.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,417 shares of the specialty chemicals company's stock after buying an additional 17,338 shares during the quarter. Natixis Advisors LLC owned approximately 0.26% of Cabot worth $11,757,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Invesco Ltd. raised its stake in shares of Cabot by 7.1% during the 4th quarter. Invesco Ltd. now owns 845,261 shares of the specialty chemicals company's stock worth $77,181,000 after acquiring an additional 55,905 shares in the last quarter. Copeland Capital Management LLC grew its position in Cabot by 5.8% during the 1st quarter. Copeland Capital Management LLC now owns 805,504 shares of the specialty chemicals company's stock worth $66,970,000 after purchasing an additional 44,132 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Cabot by 12.4% in the 4th quarter. Northern Trust Corp now owns 794,477 shares of the specialty chemicals company's stock valued at $72,544,000 after acquiring an additional 87,881 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Cabot by 27.1% in the 4th quarter. JPMorgan Chase & Co. now owns 451,513 shares of the specialty chemicals company's stock valued at $41,228,000 after acquiring an additional 96,179 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Cabot in the 4th quarter valued at $37,961,000. Institutional investors own 93.18% of the company's stock.
Cabot Price Performance
Shares of NYSE CBT traded down $0.23 during mid-day trading on Thursday, reaching $77.61. The company's stock had a trading volume of 232,679 shares, compared to its average volume of 430,110. The stock has a 50-day moving average of $75.86 and a two-hundred day moving average of $79.72. The stock has a market capitalization of $4.17 billion, a P/E ratio of 10.13 and a beta of 0.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.30 and a current ratio of 2.13. Cabot Corporation has a 1-year low of $70.40 and a 1-year high of $117.46.
Cabot (NYSE:CBT - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The specialty chemicals company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.10. Cabot had a net margin of 11.14% and a return on equity of 25.68%. The firm had revenue of $923.00 million during the quarter, compared to analyst estimates of $957.29 million. On average, equities research analysts anticipate that Cabot Corporation will post 7.57 EPS for the current fiscal year.
Cabot Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 29th will be paid a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a yield of 2.3%. Cabot's dividend payout ratio (DPR) is presently 23.53%.
Wall Street Analysts Forecast Growth
CBT has been the topic of several recent research reports. UBS Group set a $82.00 price objective on shares of Cabot and gave the company a "neutral" rating in a report on Tuesday. Wall Street Zen cut shares of Cabot from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th.
View Our Latest Stock Analysis on CBT
Cabot Profile
(
Free Report)
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Read More

Before you consider Cabot, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.
While Cabot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.